Research programme: encapsulated cell therapies - Eli Lilly\Sigilon Therapeutics

Drug Profile

Research programme: encapsulated cell therapies - Eli Lilly\Sigilon Therapeutics

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sigilon Therapeutics
  • Class Antihyperglycaemics; Cell therapies; Gene therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Type 1 diabetes mellitus

Most Recent Events

  • 04 Apr 2018 Eli Lilly and Sigilon Therapeutics enter into a global collaboration agreement to develop encapsulated cell therapies for Type 1 diabetes
  • 04 Apr 2018 Early research in Type-1 diabetes mellitus in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top